Quitting smoking with varenicline: Parallel, randomised efficacy trial in Iran

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 2, 2012, Pages 268-272

  Heydari, G ^a   Talischi, F ^b   Tafti, Saeid Fallah ^b   Masjedi, M R ^b  

^a Tobacco Prevention and Control Research Centre   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Medication therapy management; Smoking cessation; Varenicline

Indexed keywords

NICOTINE PATCH; VARENICLINE;

ABNORMAL DREAMING; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BEHAVIOR THERAPY; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NICOTINE REPLACEMENT THERAPY; PARALLEL DESIGN; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADULT; BENZAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRAN; MALE; NICOTINIC AGONISTS; PREVALENCE; QUINOXALINES; RETROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84855654003     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0183     Document Type: Article

References (19)

1. Jones J M. Smoking habits stable; most would like to quit. Princeton, NJ, USA: Gallup, 18 July 2006. http://www.gallup. com/poll/23791/Smoking-Habits- Stable-Most-Would-Like- Quit.aspx Accessed October 2011.
2. Solberg L I, Maciosek M V, Edwards N M, Khanchandani H S, Goodman M J. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. Am J Prev Med 2006; 31: 62-71.
3. West R, Sohal T. 'Catastrophic' pathways to smoking cessation: findings from national survey. BMJ 2006; 332: 458-460. (Pubitemid 43342044)
4. Owen L. Impact of a telephone helpline for smokers who called during a mass media campaign. Tobacco Control 2000; 9: 148-154.
5. Pfizer. Pfizer for professionals. Mechanism of action of CHANTIX™ (varenicline). New York, NY, USA: Pfizer, 2007. https://www.pfizerpro.com/ product-info/chantix-dual-action. jsp Accessed October 2011.
6. Tobacco Advisory Group of the Royal College of Physicians. Nicotine addiction in Britain: a report of the Tobacco Advisory Group of the Royal College of Physicians. London, UK: RCP London, 2000. http://bookshop.rcplondon. ac.uk/details. aspx?e=131 Accessed November 2011.
7. Hughes J R, Rennard S L, Fingar J R, Talbot S K, Callas P W, Fagerström K O. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebocontrolled trial. Nicotine Tob Res 2011; 13: 955-964.
8. Gray K M, Carpenter M J, Lewis A L, Klintworth E M, Upadhyaya H P. Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomised, double-blind pilot trial. Nicotine Tob Res 2011; Jul 20. [e-pub ahead of print]
9. Gonzales D, Rennard S I, Nides M, et al., Varenicline Phase 3 Study Group. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation. JAMA 2006; 296: 47-55.
10. Jorenby D E, Hays T, Rigotti N A, et al., Varenicline Phase 3 Study Group. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006; 296: 56-63.
11. Tonstad S, Tønnesen P, Hajek P, et al., Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64-71.
12. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; 4: CD000165.
13. Rice V, Stead L F. Nursing interventions for smoking cessation. Cochrane Database Syst Rev 2004; 1: CD001188.
14. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55: 987-999.
15. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; 3: CD000146.
16. British Thoracic Society. Comparison of four methods of smoking withdrawal in patients with smoking related disorders. BMJ 1983; 286: 595-597.
17. Lancaster T, Stead L F. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005; 2: CD001292.
18. Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost-effectiveness of smoking cessation interventions. Thorax 1998; 53 (Suppl 5); S1-S38.
19. Dale L C, Glover E D, Sachs D P, et al. Bupropion for smoking cessation: predictors of successful outcome. Chest 2001; 119: 1357-1364. (Pubitemid 32686015)